GlassScriptPhysician profile
Ahmed Deabes
NPI 1255648648
$5,840.35
in general payments reported to CMS, 2019-2025
27 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.43 · 2020: $49.14 · 2021: $690 · 2022: $949 · 2023: $1,246 · 2024: $1,427 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,032 · Education: $24.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,032.07 |
| Education | $24.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,716.76 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $725.38 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $724.69 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $524.25 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $374.15 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $324.90 | 2021-2025 | Tremfya, Stelara |
| Merck Sharp & Dohme LLC | $235.89 | 2021-2024 | Dificid, Recarbrio |
| Pfizer INC. | $211.60 | 2020-2025 | |
| Intercept Pharmaceuticals, INC. | $144.09 | 2023-2025 | Ocaliva |
| Qol Medical, LLC | $106.22 | 2021-2024 | Sucraid |
| Phathom Pharmaceuticals, INC. | $102.29 | 2024-2025 | Voquezna |
| Vivus LLC | $83.75 | 2023-2025 | Qsymia |
| Redhill Biopharma INC. | $79.92 | 2023-2024 | Talicia |
| Braintree Laboratories, INC. | $75.92 | 2022-2024 | Suflave, Sutab |
| Ardelyx, INC. | $75.91 | 2024-2025 | Ibsrela |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $57.55 | 2024-2025 | |
| Enterra Medical, INC. | $51.58 | 2022 | |
| Aimmune Therapeutics, INC. | $39.32 | 2025 | Vowst |
| Lilly USA, LLC | $30.57 | 2025 | Omvoh |
| Celltrion USA INC. | $24.65 | 2024 | Zymfentra |
| Novo Nordisk INC | $23.16 | 2025 | Wegovy |
| Orphalan INC | $21.66 | 2023 | Cuvrior |
| Ferring Pharmaceuticals INC. | $19.60 | 2025 | Rebyota |
| Steris Corporation | $18.99 | 2025 | |
| Madrigal Pharmaceuticals | $18.71 | 2025 | Rezdiffra |
| Pentax of America, INC. | $15.10 | 2022 | |
| Shionogi INC | $13.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Deabes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.